A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

NCT05657418 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Company research and development strategy adjustment

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG: JS107
COMBINATION_PRODUCT: JS107 combination with Toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.